Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 3Terminated 2Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Advanced Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 20Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Doxorubicin 10Radiotherapy 9Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Etoposide 7Leucovorin 6Ipilimumab 6Injections 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Prednisone 5Pemetrexed 5Methotrexate 5Cetuximab 5Bevacizumab 5fludarabine 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Axitinib × 30 days × Clear all
NCT05017012 2026-06-05

MK-3475A-C18

Merck Sharp & Dohme LLC

Phase 1 Completed
142 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05420220 2026-05-28

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Completed
95 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡